 NGM707 was generally well tolerated to the highest dose evaluated 1800 mg in the monotherapy escalation; maximum tolerated dose was not reached Linear pharmacokinetics PK was observed at doses 200 mg, and analysis of peripheral immune cells demonstrated dose-dependent receptor occupancy RO, with doses 200 mg maintaining full ILT2 and ILT4 RO for the entire ... The post NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or... 